Validation of the French Version of the Low Anterior Resection Syndrome (LARS) Among Rectal Cancer Patients (LARS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03569488|
Recruitment Status : Recruiting
First Posted : June 26, 2018
Last Update Posted : June 17, 2020
Oncological rectal cancer outcomes have improved considerably because of optimal surgery by total mesorectal excision in conjunction with multidisciplinary team management by selective multimodal therapy (ie, neo-adjuvant chemo-radiotherapy). The 5-year survival has increased to more than 50% and local recurrence has been reduced to less than 10%. These advancements have resulted in more patient receiving sphincter-preserving surgery (SPS). With an increasing number of rectal cancer survivors, the investigators observe a rising attention to the disordered bowel function after SPS, called "low anterior resection syndrome" (LARS). LARS appear immediately after surgery, becoming most pronounced during the first few months, and improved thereafter, reaching a steady state after around two years. However, up to 60% of patients with SPS suffer from LARS which impaired their quality of life (QoL). The prevalence and severity of LARS is difficult to assess due to heterogeneity of the assessment tools. A group of Danish authors have recently developed and validated a five-item instruments for evaluation of LARS (LARS score). It represents to date the best questionnaire to capture anorectal postoperative function and consists of five items: incontinence for flatus, incontinence for liquid stool, frequency of bowel movements, clustering of stools, and urgency. It allows a categorization of patients into 3 groups: no LARS (0-20 points), minor LARS (21-29 points), and major LARS (30-42 points). Developed in Danish, it is now internationally validated with translations in Chinese, English, German, Spanish and Swedish. To our knowledge, French version of the LARS score is not yet available. The aim of our study will be to adapt the LARS scale questionnaire to the French language (LARS-F), and assess its psychometric properties.
Inclusion criteria will be patients 18 years old or above who were operated for rectal cancer from 2007 to 2015. Exclusion criteria will include the presence of stoma and/or known disseminated or recurrent disease. Patients will be identified through local databases by the local investigators at each of the participating centers with a minimum duration of 24 months after surgery to allow their bowel function to have regained stability. This study will be supported by the French Research Group of Rectal Cancer Surgery in order to allow the feasibility of the project.
After translation/back-translation procedures in accordance with the permission from the original authors, the LARS-F score and the whole translation process will be then sent to the original authors for approval. Then a pilot study will be conducted. The French questionnaire (LARS-F score) will be then administered to 100 patients in order to verify the adequacy and degree of comprehension of the questions. Reproducibility will be investigated by a test-retest procedure. A randomly selected subgroup of participants (n= 400) will be sent the LARS-F score questionnaire twice (with an interval of two weeks). The test-retest reliability of the questionnaire will be assessed by the Cohen's Kappa (no, minor and major LARS scores) or by intra-class correlation coefficient, ICC (quantitative LARS score). Then, eligible patients will receive a postal invitation to complete the LARS-F score and the l'European Organization for Research and treatment of Cancer (EORTC) QLQ-C30 and QLQ-CR29, respectively. The validity of the LARS-F score will be tested by using the indicators of convergent validity and discriminant validity. The convergent validity will be determined notably in this study by computing the correlations between the LARS-F score and the EORTC QLQ-C30 and QLQ-CR29 domains. For discriminant validity testing, the investigators will use known variables to affect bowel function after SPS, such as gender, age, neo-adjuvant radiation therapy, distance of the tumor from the anal verge, prior temporary stoma, and length of postoperative period.
The validation of the French version of the LARS score will allow to use a scientific instrument in order to assess both prevalence and severity of LARS. This instrument will allow to develop a future research and clinical practice in France. It will be used in the daily clinical practice to identify patients with LARS score. It will hopefully lead to improve the awareness of clinicians, in order to improve the prevention and the treatment of bowel dysfunction, as well as the information given to patients. In the future, the investigators will able to develop a new patient-led follow-up program based on symptom burden and health-related QoL.
|Condition or disease||Intervention/treatment|
|Rectal Cancer Patients||Diagnostic Test: FT-LARS questionnaire|
- Age between 18 and 80 years
- Rectal cancer patients undergoing curative sphincter-preserving surgery with partial or total mesorectal excision
- Surgery performed between January 2007 to January 2016, with reversal of the defunctioning stoma before January 2016;
- Hence all patients had had bowel continuity restored for at least 24 months Voluntarily participated in the study
- The presence of stoma and/or known disseminated or recurrent disease
- Other diseases of bowel dysfunction (Crohn's disease)
- Cognition and/or language issues.
Detailed description of the implemented techniques
-The validation study of the French version of the LARS score is based on one hand on the face and content validities and on the other hand on the measurement of its psychometric properties in compliance with the standards published by American Educational Research Association & al.
- After translation/back-translation procedures in accordance with the permission from the original authors, the LARS-F score and the whole translation process will be then sent to the original authors for approval. Then, eligible patients will receive a postal invitation to complete the LARS-F score and the l'European Organization for Research and treatment of Cancer (EORTC) QLQ-C30 and QLQ-CR29, respectively. For each item, ceiling and floor effects will be sought.
- The reliability will be assessed by both internal consistency (Cronbach's alpha coefficient).
- To evaluate reproducibility, a test-retest study will be performed in a randomly selected subgroup patients by comparing LARS-F scores obtained between the patient's first and second postal invitation (in an interval of 7-14 days).
- The correlations between the LARS-F score and the EORTC QLQ-C30 and QLQ-CR29 domains will allow to determine convergent validity. For discriminant and divergent validities testing, we will hypothesize that the LARS score will differentiate between the bowel functions of patients with different demographic or clinical features such as sex, age, length of postoperative period, distance of the tumor from the anal verge, radiation therapy, and prior temporary stoma.
- Sensitivity and specificity for minor and major LARS scores will be assessed.
|Study Type :||Observational|
|Estimated Enrollment :||1100 participants|
|Official Title:||Validation of the French Version of the Low Anterior Resection Syndrome (LARS) Score for Measuring Bowel Dysfunction After Sphincter-preserving Surgery Among Rectal Cancer Patients|
|Actual Study Start Date :||January 24, 2020|
|Estimated Primary Completion Date :||May 30, 2022|
|Estimated Study Completion Date :||May 30, 2023|
- Diagnostic Test: FT-LARS questionnaire
- validation of the French version of the LARS score [ Time Frame: baseline ]
- Cross cultural adaptation
- Internal consistency
- Face validity and content validity
- Floor effect - Ceiling effect
- Convergent validity and Divergent validity
- Known-group method and relationship between each item and subscales
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03569488
|Amiens, France, 60000|
|Contact: jean marc regimbeau, MD,PhD 03 22 08 88 93 email@example.com|
|Caen University Hospital||Recruiting|
|Contact: Arnaud Alvès, MD, PhD 0231064497 firstname.lastname@example.org|
|Lille, France, 59000|
|Contact: guillaume piessen, MD, PhD 03 20 44 44 07 email@example.com|
|Centre Oscar Lambret||Recruiting|
|Contact: Merhdad JAFARI, MD-PhD 0320295920 firstname.lastname@example.org|
|Nancy, France, 57000|
|Contact: laurent bresler, MD, PhD 03 83 15 31 20 email@example.com|
|Contact: guillaume meurette, MD,PhD 02 40 08 30 41 firstname.lastname@example.org|
|Contact: EMILIE DUCHALAIS DASSONVILLE, MD Emilie.DASSONNEVILLE@chu-nantes.fr|
|Contact: mehdi ouaissi, MD, PhD 02 47 47 01 87 M.OUAISSI@chu-tours.fr|
|clc VANDEUVRE LES NANCY||Recruiting|
|Vandœuvre-lès-Nancy, France, 57000|
|Contact: frédéric marchal, MD,PhD 03 83 59 84 51 email@example.com|